Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer

Phase

1/2

Condition

Anal Dysplasia

Treatment

BMX-001

Clinical Study ID

NCT03386500

0247-17-FB

Ages > 19
All Genders

Study Summary

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients with pathologically confirmed locally advanced anal squamous cell carcinoma (including oligometastatic disease) who will be receiving concurrent chemoradiationwith standard 5FU/Mitomycin regimen with curative intent.
Any cancer stage that will require a dose of 59.4 cGy.
Age ≥ 19 years
Karnofsky Performance Status (KPS) ≥ 60%
Hemoglobin ≥ 9.0 g/dl, ANC ≥ 1,500 /dl, platelets ≥ 100,000 /dl (The use oftransfusion or other intervention to achieve Hgb > 9.0 g/dl is acceptable)
Serum creatinine ≤ 1.5 mg/dl, serum SGOT and bilirubin ≤ 1.5 times upper limit ofnormal
Signed, written informed consent
Negative pregnancy test for women of child-bearing potential within 48 hours priorto first dose of BMX-001
Women of childbearing potential and male participants must agree to use a medicallyeffective means of birth control throughout their participation in the treatmentphase of the study and until 12 months following the last study treatment
PET/CT/ pelvic MRI done within 8 weeks of trial initiation

Exclusion

Exclusion Criteria:

Breast-feeding
Active infection requiring IV antibiotics 7 days before enrollment
Prior, unrelated malignancy requiring current active treatment with the exception ofcervical carcinoma in situ, basal cell or carcinoma of the skin, invasive cancerswith a 5-year disease-free interval, resected cancer of the bladder or low-grade (Gleason 6 or less) prostate cancer
Prior history of ASCC
Prior history of pelvic radiotherapy for any other type of malignancy
Known hypersensitivity to 5FU and/or mitomycin
Because corticosteroids are anti-inflammatory and could interrupt oxidative stress,patients will be required to be on stable or decreasing corticosteroids dose at thetime of the study.
Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHgand/or diastolic blood pressure > 100 mmHg)
Active or history of postural hypotension and autonomic dysfunction within the pastyear
Known hypersensitivity to BMX-001
Clinically significant (i.e. active) cardiovascular disease or cerebrovasculardisease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment,myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, NewYork Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), orserious cardiac arrhythmia uncontrolled by medication or potentially interferingwith protocol treatment
History or evidence upon physical/neurological examination of central nervous systemdisease (e.g. seizures) unrelated to cancer unless adequately controlled bymedication or potentially interfering with protocol treatment
Significant vascular disease (e.g., aortic aneurysm requiring surgical repair orrecent arterial thrombosis) within 6 months prior to start of study treatment
A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of aQTc interval >480 milliseconds (ms) (CTCAE grade 1) using the specific/usual choiceby clinical center for correction factor.
A history of additional risk factors for Torsades de Pointes (TdP) (e.g., congestiveheart failure, hypokalemia, known family history of Long QT Syndrome).

Study Design

BMX-001

1/2

November 28, 2017

December 31, 2029

Study Description

In this Phase 1/2 study, the investigators will conduct a safety and efficacy study of the combination of BMX-001 with standard radiation therapy (RT) and concurrent 5-fluorouracil (5FU)/mitomycin in newly diagnosed Anal Squamous Cell Carcinoma (ASCC) patients. At the time of writing of this protocol amendment, another Phase 1 study using BMX-001 with concurrent chemotherapy and radiation therapy in patient with newly diagnosed high-grade gliomas (BMX-HGG-001) has completed. This clinical trial has demonstrated no adverse effects in subcutaneous dosing up to 28 mg/subject load with half the loading dose (14 mg/subject) given biweekly for 8 weeks in 12 subjects. Three subjects were enrolled and dosed with 42 mg/subject load with half the loading dose given biweekly for 8 weeks. Of these three subjects, there was one dose-limiting toxicity of grade 3 tachycardia and grade 3 hypotension. The DLT in this subject occurred with the loading dose (42 mg sc). The patient was treated with fluids and hospital admitted for observation for 24 hours during which time the hypotension and tachycardia resolved. The cardiac rhythm was a sinus tachycardia and no other cardiac toxicity was observed. The tachycardia was assumed to have resulted from hypotension occurring following the sub-cutaneous injection of BMX-001 (42 mg). After the loading dose of BMX-001 and the described DLT, the subject continued on study and experienced no tachycardia or hypotension following administration of the subsequent 16 maintenance doses (20 mg sc). The sponsor determined that the Recommended Phase 2 Dose (RP2D) of BMX-001 is 28 mg/subject load followed by 14 mg/subject twice a week for up to eight weeks. This is the maximum dose that was tolerated with no adverse effects.

The most common related toxicity seen in the Phase 1 BMX-HGG-001 trial was grade 1 injection site reaction. There is no apparent toxicity to end organ tissues or bone marrow.

The completion of a Phase 1 clinical trial in patients with high-grade glioma undergoing brain radiation therapy plus chemotherapy with temozolomide has established the RP2D for BMX-001. The RP2D by sub-cutaneous injection is 28 mg/subject load followed by a maintenance dose of 14 mg/subject b.i.w. At the RP2D, there have been no BMX-001 dose limiting toxicities observed.

Based on the completion of Phase 1 and establishment of a RP2D for this treatment regimen in patients undergoing radiation therapy and chemotherapy, the clinical trial described in this protocol of patients with newly diagnosed ASCC will proceed to Dose Level 3, after completion of Dose Level 1 and Dose Level 2, enrolling up to 20 subjects with a safety lead-in of 6 subjects. The reason for the safety lead-in is to confirm safety in subjects in this cohort receiving radiation therapy and 5FU/mitomycin.

In order to evaluate the pharmacokinetics (PK) of BMX-001 in combination with current chemoradiation, blood samples will be drawn for analysis in the a minimum of three and up to 6 patients in enrolled in the safety lead-in.

In this trial, the first dose of BMX-001 will be administered subcutaneously from 4 days up to 1 hour prior to the start of radiation treatment.

Blood will be drawn for PK on the following days: Day 1 (before and after loading dose), Day 8, Day 22 and Day 36. Measures will be obtained at approximately the following times: -1 to 0 hour (before loading dose), 30 minutes after the drug is given, 4 hours post-dose, and 24 hours post-dose. This is described in Appendix A. Samples will be analyzed for BMX-001 using validated analytical methods at Dr. Ivan Spasojevic's laboratory at Duke University.

Skin, GI, and GU symptoms will be measured on the day of screening, weekly during RT, 1 months, 4 months and 10 months after the completion of RT. Perianal skin will be assessed weekly during RT, 1 month, 4 months, and 10 months after completion of RT. Further follow up will be per standard of care.

Connect with a study center

University of Nebraska Medical Center
Omaha, Nebraska 68198
United States
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.